Two European manufacturing plants discarded by Big Pharma have been bought by Asian companies and reopened.
U.S biotech Evolus alerted investors that FDA concerns with a Daewoong plant in South Korea that will make its Botox copy could delay its approval.
China’s Clover Biopharmaceuticals expects to have a biologics facility completed by year-end where it will produce its Enbrel biosimilar candidate.
An Indian company that has had its drugs banned by the FDA has bought a contract manufacturing operation in the U.S.
Celltrion Chairman Seo Jeong-jin has confirmed that the South Korean drugmaker has decided to build its third plant outside of South Korea.
The EMA has decided to block the API for amoxicillin trihydrate produced by a company in China whose manufacturing oversight has been lacking.
Samsung is tamping down investor excitement about a fourth biologics manufacturing site after one of its execs suggested it could be built sooner.
With plans for further expansion in China, Japan’s Eisai has opened a new solid dose plant in Suzhou.
Athenex is moving forward with a project to build a $210 million manufacturing plant in New York that will be financed primarily by the state.
GlaxoSmithKline said it is cutting an undisclosed number of jobs at its Irvine plant in North Ayrshire, Scotland.